FDA Proposes Faster Pathway for Rare Disease Therapies Using Gene Editing

The US Food and Drug Administration (FDA) has proposed new guidelines to hasten access to tailored therapies for rare diseases. The move aims to remove obstacles for experimental treatments, including advanced gene-editing solutions. Under the plan, therapies tested on only a small number of patients could gain approval more easily than before.

The proposed pathway, named 'plausible mechanism', would apply to well-studied conditions where treatments directly target the disease's genetic or cellular roots. Unlike the current compassionate use process, this route could eventually allow for commercialisation of such therapies.

In 2023, a CRISPR-based therapy called CASGEVY (exagamglogene autotemcel) was tested on 15 patients suffering from sickle cell anaemia and beta-thalassemia. Developed by researchers at the Children's Hospital of Philadelphia and the University of Pennsylvania, the treatment was part of clinical trials. The FDA's new approach would consider similar cases where a therapy has successfully addressed a patient's specific genetic or biological abnormality.

Before finalising the rules, the agency will accept public comments on the draft guidance for 60 days. Officials have stressed that the priority is to reduce barriers and foster innovation in treatments for rare diseases.

The FDA's proposal could open doors for more personalised therapies to reach patients faster. If adopted, the pathway would focus on conditions where the underlying biology is clearly understood. Developers of gene-editing and other targeted treatments may soon have a clearer route to approval.